US · Healthcare · Medical Devices
EPS came in at -0.39 against a street estimate of -0.34 — a miss of 14.7%.
Analysts rate Establishment Labs Holdings Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $102.44.
CONFIDENT Q2 beat with $67.5M revenue (+31.7% YoY), raised FY26 guidance to $269–271M. U.S. surged 141%, minimally invasive (Mia/Preservé) at 18% of mix. Path to FCF-positive H2 2026. Reconstruction FDA progress ongoing. Q2 FY26 U.S. now 36.6% of revenue vs. 20% year-ago. Europe direct markets prioritized; management emphasizing shift away from distributor-dependency. Middle East conflict reduced orders; spillover to other markets limited so far. Analysts pressed Preservé adoption breadth, recon regulatory trajectory, and 2027 guidance assumptions. Management emphasized Preservé as category disruptor (15% new patients), recon as later driver (2027+ meaningful revenue), and 25% growth baseline excluding recon upside. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| JW Asset Management, LLC | 9.04% |
| RTW INVESTMENTS, LLC | 8.91% |
| BlackRock Inc | 5.31% |
| T. Rowe Price Associates, Inc. | 5.15% |
| Brown Advisory Holdings Inc | 4.41% |
| Findell Capital Management LLC | 3.68% |
| Mudita Advisors LLP | 2.43% |
| William Blair Investment Management, LLC | 2.40% |
| Document | Date |
|---|---|
| Material agreement · Q4 2026 BUSINESS & SEGMENT HIGHLIGHTS • On October 14, 2026, Establishment Labs Holdings Inc., through wholly owned subsidiary Establishment Labs, S.A. (ELSA | 2026-10-15 |
| Quarterly report · Q2 2026 ESTABLISHMENT LABS HOLDINGS INC. — FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Revenue (6 months 2026): $127.4 million vs. | 2026-08-07 |
| Results announced · Q3 2026 ESTABLISHMENT LABS HOLDINGS INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $67.5 million, up 31.7% year-over-year from $51.3 m | 2026-08-06 |
| Board / officer change · Q2 2026 ESTABLISHMENT LABS HOLDINGS INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company is Establishment Labs Holdings Inc., a medical device/he | 2026-06-29 |
| Shareholder vote results · Q2 2026 ESTABLISHMENT LABS HOLDINGS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Shareholders held May 22, 2026 • Company ticker: ESTA (Nasd | 2026-05-22 |
| Quarterly report · Q1 2026 ESTABLISHMENT LABS HOLDINGS INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q1 2026: $59.9 million (up 44.7% vs. Q1 2025: $41.4 million) • Ne | 2026-05-08 |
| Results announced · Q2 2026 ESTABLISHMENT LABS Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenue Q1 2026: $59.9 million, up 44.7% year-over-year from $41.4 million in | 2026-05-06 |
| Proxy statement · Q2 2026 ESTABLISHMENT LABS HOLDINGS INC. — 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 (Election of Directors): Elect six director nomin | 2026-04-10 |
Readable in the app.
| Announcement | Date |
|---|---|
| Master supply agreement extended through 2031 for medical-grade silicone products Establishment Labs extended its supply agreement with NuSil Technology, a supplier of medical-grade silicone used in certain of its products. The amendment is effective January 1, 2027, and | 2026-10-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Establishment Labs Holdings Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.